Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network / Christiane Pott, Wolfram Klapper, Christian Schmidt, Michael Unterhalt, Martin Dreyling, Jeanette Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trneny, Vibeke K. J. Vergote, Ofer Shpilberg, Maria Gomes da Silva, Tobias Tix, Marco Ladetto, Eva Hoster, Alexandra Albertsson Lindblad, Virginia Amador, Guilherme Brasil Duffles Amarante, Luca Arcaini, Rebecca Auer, Igor Aurer, Avigdor Abraham, Irit Avivi, Enver Aydilek, Sandra Bašić-Kinda

Related documents

• A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome#830375
• A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease#1365712
• Einfluss bestrahlter Endothelzellen auf das Metastasierungsverhalten von Brustkrebszellen in vitro / Carolin Norra ; Gutachter: Guido Hildebrandt, Franz Rödel, Steffi Hartmann#814496
• Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells#1113027
• Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products#1095230